Failure to maintain clinical response · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.58 [0.48, 0.71]
Studies not reported
Moderate
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Cardiovascular mortality · people with CKD (including HD and PD)
It is very uncertain whether hypoxia‐inducible factor (HIF) stabilisers changes cardiovascular death Median compared with placebo (very low certainty).
1 finding from 1 review
Fatigue · people with CKD (including HD and PD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Life participation · people with CKD (including HD and PD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nonfatal myocardial infarction Median · people with CKD (including HD and PD)
It is very uncertain whether hypoxia‐inducible factor (HIF) stabilisers changes nonfatal myocardial infarction Median compared with placebo (very low certainty).
1 finding from 1 review
Nonfatal stroke Median · people with CKD (including HD and PD)
1 finding from 1 review
Blood transfusion · people with CKD (including HD and PD)
Hypoxia‐inducible factor (HIF) stabilisers probably leads to lower proportion of patients requiring blood transfusion Median compared with placebo (moderate certainty).
1 finding from 1 review
Proportion reaching target haemoglobin Median · people with CKD (including HD and PD)
Hypoxia‐inducible factor (HIF) stabilisers probably leads to higher proportion reaching target haemoglobin Median compared with placebo (moderate certainty).
1 finding from 1 review
Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · people with primary open‐angle glaucoma or ocular hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Average number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Core symptoms of autism · Children aged 6 to 18 years with ASD
1 finding from 1 review
Adverse effects sufficient to stop treatment · Children aged 6 to 18 years with ASD
Memantine showed no clear difference in adverse effects Assessed by the study authors as those that were… compared with placebo (low certainty).
1 finding from 1 review
Language · Children aged 6 to 18 years with ASD
1 finding from 1 review
Memory (specific cognitive function) · Children aged 6 to 18 years with ASD
1 finding from 1 review